Extra-adrenal sympathetic paraganglioma

Summary

Extra-adrenal sympathetic paraganglioma (MONDO:0000550) is a disease. A subtype of sympathetic paraganglioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	extra-adrenal sympathetic paraganglioma
Mondo ID	MONDO:0000550
EFO	EFO:0000489
DOID	DOID:0050936
NCIT	C48576
UMLS	C1257877
MedGen	263453
GARD	0022801
Is cancer (heuristic)	no

Also known as: extra-adrenal chromaffin neoplasm · extra-adrenal Chromaffinoma · extra-adrenal pheochromocytoma · extra-adrenal sympathetic paraganglioma · extra-adrenal sympathetic Paraganglionic neoplasm · extraadrenal pheochromocytoma

Disease family

This is a subtype of sympathetic paraganglioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › autonomic nervous system disorder › autonomic nervous system neoplasm › paraganglioma › sympathetic paraganglioma › extra-adrenal sympathetic paraganglioma

Related subtypes (1): adrenal gland pheochromocytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.